Back to Education Zone

touchCONGRESS Webinar

Will a scientific breakthrough translate into clinical benefits in nAMD? Highlights from EURETINA 2019


Stay up to date with the latest developments in the management and treatment of patients with nAMD with our expert summary from the 19th EURETINA Congress in Paris, France, 5–8 September 2019.

Professor Anat Loewenstein of the Tel Aviv Medical Center reviews the most important emerging data presented at the 19th EURETINA Congress and discusses their potential impact for addressing real-life clinical unmet needs in nAMD.

The information in this activity is intended for retina specialists and other healthcare professionals involved in the treatment of patients with nAMD.

Learning Objectives

After watching this touchCONGRESS Webinar, you should be able to:

  • Illustrate how retinal fluid may be used as a marker of disease activity and to guide individualized therapeutic strategy
  • Define the importance of patient adherence to treatment on clinical outcomes and the factors that impact adherence and QoL
  • Explain how smaller sized anti-VEGF antibodies may address the real-life unmet needs and confer clinical benefits

Clinical Spotlight

  • Why is retinal fluid important as a marker of disease activity in patients with nAMD? Focus on the rationale for and evidence to support using retinal fluid as a marker
  • How could the burden of nAMD be reduced, and patient adherence and QoL improved? Focus on treatment regimens that improve patient outcomes
  • What are the potential benefits of a smaller-size anti-VEGF therapy on dosing? Focus on how the dosing benefits of smaller-sized anti-VEGF therapies may impact clinical outcomes

Please feed back on this touchCONGRESS Webinar on the following:
(scale 1–5, 1 strongly disagree; 5 strongly agree).

Prof. Anat Loewenstein

Anat Loewenstein is the Chair of the Department of Ophthalmology, Tel Aviv Medical Centre and Professor of Ophthalmology and Vice Dean, Tel Aviv University. An expert in retinal toxicity with a strong research interest in the early detection of retinal disease, Prof. Loewenstein has served as the principal investigator of many clinical trials of anti-VEGF agents and steroid implants for the treatment of retinal disorders such as age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Prof. Loewenstein is currently the General Secretary of EURETINA.

Disclosures: Advisory role with Allergan, Bayer, BeyeOnics, Notal Vision, Novartis, Pres-By, Roche and Syneos Health. Research funding from Allergan, Bayer and Novartis.

touchCONGRESS Expert Interviews

Watch internationally regarded ophthalmology experts discuss the latest developments in imaging and anti-VEGF agents for neovascular age-related macular disease presented at EURETINA 2019 in Paris, France, 5–8 September 2019.

Watch Now